Biologics Transform Type 2 Asthma Management, Emerging Strategies Target Non-Type 2 and Steroid-Resistant Phenotypes
Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.
Abstract
Current biologics effectively manage severe Type 2 asthma, while emerging therapies and personalized strategies target Type 1 and steroid-resistant phenotypes, facing challenges in cost and accessibility.